DARPP-32 knockdown sensitizes gefitinib-resistant NSCLC tumors to EGFR inhibition in vivo, whereas no such effect was observed in mice challenged with control LacZ shRNA-transduced HCC827GR cells (Fig. 7b and Supplementary Fig. 13a). The gene discussed is PPP1R1B; the disease is non-small cell lung carcinoma.